-

Bayer Earns Top Honors with 2021 Military Friendly ® Employer Designation

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has earned recognition as a 2021 Military Friendly ® Employer.

The designation recognizes the company’s proactive efforts to honor, include and encourage veterans and military members through its workplace policies. Such policies at Bayer include expanding health benefits for family members while the employee is deployed, providing employer-sponsored life insurance, and closing the pay gap between the employee’s military pay and Bayer pay for up to two years while deployed.

In addition, Bayer’s military business resource group BRAVE attracts, mentors, and develops veteran and military member talent. Through BRAVE, Bayer is an enthusiastic sponsor of events and initiatives that further support and amplify the voices of these employees. The group, which is open to all veterans, military members, and allies who are passionate about honoring those who served our country, is actively involved in the communities Bayer calls home, and it fosters opportunities within the company to engage its 500+ members.

Companies and organizations earning the Military Friendly ® Employer designation were evaluated using both public data sources and responses from a proprietary survey. Hundreds of companies participated in the Military Friendly ® Employers portion of the 2021 Military Friendly ® Companies survey. Methodology, criteria, and weightings were determined by VIQTORY with input from the Military Friendly ® Advisory Council of independent leaders in the higher education and military recruitment community. Final ratings were determined by combining an organization’s survey score with an assessment of the organization’s ability to meet thresholds for Applicant, New Hire Retention, Employee Turnover, and Promotion & Advancement of veterans and military employees.

“To be recognized with this designation is not only an honor for Bayer, but it is a proud testament to our priorities as a company,” said Raymond F. Kerins, SVP and Head of Corporate Affairs for Bayer in the U.S. and Co-executive Sponsor of BRAVE. “The courageous men and women of our country’s armed forces have earned the respect and admiration of all Americans through their spirit of self-sacrifice and their service to their country. It is equally important that we recognize the skills, talent and character that they add to the workplace.

“These heroes bring such incredible value to the table at Bayer, and we are honored to be held up as an example of a company that is a great place for them to work.”

“Companies that have earned this designation have invested in substantive programs to recruit, retain and advance veterans within their organizations,” said Josh Rosen, Director of Military Friendly ®. “To them, hiring veterans isn’t just the right thing to do. It’s good for business.”

Bayer will be showcased along with other 2021 Military Friendly ® Employers in the December issue of G.I. Jobs ® magazine and on MilitaryFriendly.com.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

About Military Friendly ® Employers:

The Military Friendly ® Employers list is created each year based on extensive research using public data sources for thousands of federal contractors nationwide, the input of military employees, and responses to the proprietary, data-driven Military Friendly ® Employers survey from participating companies. The survey questions, methodology, criteria and weightings were

developed with the assistance of an independent research firm and an advisory council of educators and employers. Data calculations and tabulations were independently evaluated for

completeness and accuracy by Ernst & Young. The survey is administered for free and is open to companies that have hired veterans in the past 12 months. Criteria for consideration can be found at www.militaryfriendly.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Carolyn Nagle, +1 (201) 419-0337
carolyn.nagle@bayer.com

Bayer Logo
Bayer Logo

Bayer


Release Versions

Contacts

Carolyn Nagle, +1 (201) 419-0337
carolyn.nagle@bayer.com

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom